Biocept Inc. Total Liabilities
Biocept Inc. total liabilities. Based on the latest financial reports, Biocept Inc. (BIOCQ) has total liabilities worth $21.81 Million USD as of June 2023. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See Biocept Inc. liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Biocept Inc. (2019–2022)
Total liabilities of Biocept Inc. from 2019 to 2022. This chart illustrates how Biocept Inc.'s total liabilities have evolved over time, based on quarterly financial data.
Biocept Inc. Competitors by Total Liabilities
The table below lists competitors of Biocept Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Ethernity Networks Ltd
LSE:ENET
|
UK | GBX3.20 Million |
|
Spiritus Mundi PLC
LSE:SPMU
|
UK | GBX545.23K |
|
Ordinary Fully Paid Deferred Settlement
AU:EDEDA
|
Australia | AU$17.73 Million |
|
Lixte Biotechnology Holdings Inc
NASDAQ:LIXTW
|
USA | $521.42K |
|
Pure One Corporation Limited
AU:P1E
|
Australia | AU$11.54 Million |
Liability Composition Analysis (2019–2022)
This chart breaks down Biocept Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Biocept Inc. assets under control.
Liquidity & Leverage Metrics
Biocept Inc. Total Liabilities Ratios Explained
Biocept Inc. total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.81 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 75.22 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.99 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Biocept Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Biocept Inc. (2019–2022)
The table below shows the annual total liabilities of Biocept Inc. from 2019 to 2022.
| Year | Total Liabilities | Change |
|---|---|---|
| 2022-12-31 | $22.01 Million | -4.03% |
| 2021-12-31 | $22.94 Million | -3.46% |
| 2020-12-31 | $23.76 Million | +263.73% |
| 2019-12-31 | $6.53 Million | -- |
About Biocept Inc.
Biocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary clinical diagnostic laboratory assays designed to identify rare tumor cells and cell-free tumor DNA from blood and cerebrospinal fluid, or CSF in the United States. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients … Read more